Lung cancer has traditionally been considered relatively resistant to immunotherapies. However, recent advances in the understanding of tumor-associated antigens, anti-tumor immune responses, and tumor immunosuppression mechanisms have resulted in a number of promising immunomodulatory therapies such as vaccines and checkpoint inhibitors. Locally advanced non-small cell lung cancer is an optimal setting for these treatments because standard therapies such as surgery, radiation, and chemotherapy may enhance anti-tumor immune effects by debulking the tumor, increasing tumor antigen presentation, and promoting T-cell response and trafficking. Clinical trials incorporating immunomodulatory agents into combined modality therapy of locally advanced non-small cell lung cancer have shown promising results. Future challenges include identifying biomarkers to predict those patients most likely to benefit from this approach, radiographic assessment of treatment effects, the timing and dosing of combined modality treatment including immunotherapies, and avoidance of potentially overlapping toxicities.
T here is a clear rationale for immunotherapy in the treatment of cancer. It has long been observed that immunosuppressed individuals, such as solid organ transplant recipients or human immunodeficiency virusYpositive patients are more likely to develop malignancies. 1, 2 In contrast, small cell lung cancer patients with antibody-mediated paraneoplastic syndromes (which involve onconeural antibodies that cross-react between tumor and normal tissues) have better clinical outcomes than similar patients without these conditions. 3 In addition, for some solid tumors, intratumoral immune cell infiltration has been associated with improved outcomes. 4 Efforts to harness anti-tumor immune responses for cancer treatment date back decades. Immunotherapy in the form of allogeneic stem cell transplantation and donor T-lymphocyteinfusion is routinely used in the treatment of certain hematologic malignancies. Intravesical bacillus Calmette-Guérin administration, which generates a local inflammatory response, has become a mainstay of therapy for early-stage bladder cancer. Immune-stimulating cytokines such as interferons (IFNs) and interleukins (ILs) are established treatments for advanced melanoma and renal cell carcinoma. In 2012, the first dendritic cell vaccine (sipuleucel-T for metastatic castrate-resistant prostate cancer) was approved for cancer therapy. Recent insights into immune cell-intrinsic checkpoints have led to the development of monoclonal antibodies targeting the cytotoxic T-lymphocyteYassociated antigen 4 (CTLA-4) and the programmed death 1 (PD-1) receptor.
Historically, lung cancer has been considered resistant to immunotherapeutic strategies. It is less antigenically active than many other malignancies. There is also evidence of suppression of host immune responses; immunosuppressive T-regulatory cells and cytokines have been identified in tumor tissue, pleural effusions, and peripheral blood. 5, 6 Because most patients present with advanced disease, and existing treatments have limited efficacy in that context, it is difficult to debulk the tumor sufficiently to optimize the effects of immunotherapies. In advanced stages, bulky tumors may generate a systemic tolerogenic or immunodepressed state that renders ineffective anti-tumor immune responses. Furthermore, it may be difficult for immune effector cells to gain access to large, highly necrotic areas of bulky tumors.
In contrast to treatment paradigms for metastatic disease, the multimodality approach to locally advanced lung cancer offers several advantageous features for immunotherapy. Tumor debulking may be achieved frequently through surgery and/or radiation therapy. Surgery, radiation therapy, and chemotherapy may enhance anti-tumor immunity by increasing tumor antigen presentation, inducing immunogenic cell death, and promoting T-cell response and trafficking. 7Y11 Clinical trials of vaccines and immunotherapies in lung cancer support these observations, as patients with locally advanced disease appear to derive the greatest benefit in some cases. This review covers the rationale for and outcomes from immunotherapy in locally advanced non-small cell lung cancer (NSCLC), with sections on the components of the general immune response; mechanisms and regulation of anti-tumor immunity; interactions between anti-tumor immunity and cancer therapies (chemotherapy, radiation); and clinical experience with vaccines and other immunotherapies in locally advanced and other stages of NSCLC. A glossary of relevant terms is included in Table 1 .
TABLE 1. Glossary of Terms

Term
Definition Abscopal effect Phenomenon in which distant, nonirradiated sites of disease demonstrate regression after focal radiation treatment. Thought to reflect enhancement of anti-tumor immune responses by radiation therapy. Acquired (adaptive) immune system It is the critical task of the immune system to detect even the smallest quantities of disease-causing agents that enter the body before clinically significant harm occurs. However, in many instances, human pathogens and neoplasms have developed to elude and neutralize aspects of this immune response. In response, the human immune system has evolved to include multiple cell types and cytokines that work in concertVinnate and acquired immunity.
Innate Immune System
The innate immune system provides an immediate maximal response to pathogens butVin contrast to acquired immunityVdoes not result in lasting or repeatable protection. It includes components of both cell-mediated and humoral immunity. 12 The innate immune response is initiated in response to the release of inflammatory proteins by affected cells or by activation of specific pattern recognition receptors. The latter include (1) Toll-like receptors (TLRs), membrane-bound receptor kinases that cause cells to secrete cytokines that induce a host defense response; (2) carbohydrate-specific surface receptors including lectins and mannose receptors; (3) cytoplasmic nucleotide-binding oligomerization receptors; and (4) nucleic acidYrelated signalers. Activation of these receptors results in an inflammatory cascade that may include prostaglandins, histamines, bradykinins, and cytokines. Depending on the tissue involved, the process is then amplified by macrophages, dendritic cells, histiocytes, Kupffer cells, mastocytes, and neutrophils. 12Y15 The complement cascade serves to link this innate immune response with acquired immunity. This system includes serum proteins produced by hepatocytes that recruit inflammatory cells, coat pathogens for opsonization, perforate the plasma membranes of the pathogens resulting in cell lysis, and remove the resulting neutralized immune complex. 16 
Acquired Immune System
The acquired or adaptive immune response is more highly evolved than its innate counterpart, partly because of the genetics necessary to preserve knowledge of early pathogenic attack for future protection. This type of immunologic memory demonstrates a specificity of response to unique antigens that usually lasts for the lifetime of the host. As with the innate immune system, acquired immunity includes both cellular (mediated by T lymphocytes) and humoral (mediated by B lymphocytes) components. When an antibody on a B cell recognizes an antigen, this receptor-antigen complex is endocytosed by the B cell, the antigen is cleaved into peptides, and these peptides are presented by major histocompatibility complex (MHC) class II molecules on the surface of the B cell. In turn, these antigen-MHC complexes are recognized by helper T cells, triggering B-cell activation, and the production of more B cells producing antigen-targeting antibody ( Fig. 1 ). 12, 17 In general, this antibody response results in lifelong memoryVthat is, the ability to mount a similar response if exposed again to the same antigen. This concept provides the basis for developing vaccine strategies for combating disease. 
Term Definition
Opsonization Process by which a pathogen is marked for ingestion and destruction by a phagocyte. Involves the binding of an opsonin (eg, antibody) to a receptor on pathogen cell membrane. Subsequently, phagocytes (including macrophages) are attracted to the pathogen and ultimately engulf and destroy it.
Phagocytosis
Physical and mechanical process by which pathogens and APCs are eliminated by immune cells including macrophages as part of the final steps of the immune response to antigen.
PD-1
Cell surface protein expressed on T cells, B cells, and macrophages, which negatively regulates T-cell receptor signaling, thereby suppressing immune function; PD-1 binds to its ligand, PD-L1, on tumor or stromal cells, leading to activation and a cascade of signaling that ultimately down-regulates immune cell function. Critical for ensuring that self-tolerance limits autoimmune action. Antibodies targeting PD-1 and PD-L1 reverse T-cell suppression, promoting anti-tumor activity in clinical trials.
PD-L1
Transmembrane protein involved in suppression of immune system via binding of PD-1. Found on tumor cells and stromal cells. Blocking PD-L1 function may promote T-cell anti-tumor response.
T cell (T lymphocyte)
Any of several lymphocytes that differentiate in the thymus and possess highly specific cell-surface antigen receptors. May be involved in initiation or suppression of cell-mediated and humoral immunity (as by the regulation of T-and B-cell maturation and proliferation) or destruction of antigen-bearing cells. TLR Single membrane spanning receptor on immune cells including macrophages and dendritic cells that plays a key role in regulating the innate immune system. TLRs recognize conserved antigens from pathogens and/or tumors that stimulate innate immune responses. TLR agonists have been explored as an anti-tumor immune approach in clinical trials for lung cancer. Tolerance
Complex process by which the immune system avoids attacking unique antigens, particularly to self. A key consideration when attempting to promote anti-tumor immune responses.
TGF-A
Cytokine/growth factor involved in inflammation and immunity; thought to suppress anti-tumor immunity along with IL-10. Tumors induce the production of T cells that express IL-10 and TGF-A, thereby limiting production of adequate effector T-cell anti-tumor responses. T-regulatory cell (Treg) Suppressor T cell that maintains self-tolerance, modulates immune system, and abrogates autoimmune disease. Thought to limit T-cell immune action against tumor-associated antigens.
Vaccine
Biological preparation that improves immune responses to a particular disease. Tumor vaccines typically contain a formulation of a malignancy-specific antigen/antigens or whole-cell components that, when administered, elicits a stronger immune cell-mediated response.
Vaccination indicates the administration of an antigen for the express purpose of generating a humoral response that can be kept in the immune system's memory. Strategies for vaccine use to spur immune responses to tumor will be discussed in subsequent sections. T cells recognize pathogens presented as antigens by a variety of immune antigen-presenting cells (APCs). The process also requires complexing with another class of immune cell surface markers, the MHC. Killer T cells recognize MHC class IYantigen complexes, resulting in lysis of the targeted cell. Helper T cells identify MHC class IIYantigen complexes, resulting in cytokine release that leads to recruitment of other immune cells. Other T cells, such as gamma-delta (FC) T cells, have more specific and unique functions. 18Y20 A key characteristic of physiologic immunity is the ability to recognize self from nonself, thereby limiting autoimmune phenomena. This feature also occurs in pathological processes that escape immune surveillance, such as developing and progressing malignancies. One mechanism of achieving this escape is altering or suppressing human leukocyte antigen (HLA) expression. 21 Another is activation of inhibitory pathways that suppress T-cell function, such as those mediated by CTLA-4 and PD-1 (Fig. 2 ). 22, 23 Clinical trials are investigating the targeting of these pathways to spur anti-tumor immune responses. 23Y25
INTERPLAY BETWEEN ANTI-TUMOR IMMUNITY AND CANCER THERAPIES
The standard approach to locally advanced NSCLC entails multimodality therapyVcombinations of surgery, radiation therapy, and chemotherapy. Through various mechanisms, these treatment modalities may augment anti-tumor immunity ( Table 2) . Conversely, anti-tumor immunity may enhance the effects of these treatment modalities. Thus, there is strong rationale to incorporate vaccines and other immunotherapies into these regimens.
Surgery
There have been historical data to suggest that debulking or removal of tumor spurs a heightened inflammatory and immune state, resulting in effects against residual microscopic disease. Such concepts have been described predominantly preclinically, with only limited clinical dataVgenerally small seriesVdemonstrating these findings. 11, 26 Radiation Therapy For more than 50 years, an association between the antitumor efficacy of ionizing radiation and the local and systemic immune milieu has been recognized. 27, 28 In preclinical studies, irradiating tumor in immunodeficient animals does not yield the same degree of cell kill as in immunocompetent systems, suggesting a role for immune cells and molecules in enhancing radiation response. 27, 28 Ionizing radiation, in turn, spurs anti-tumor immunity. Specifically, ionizing radiation initiates an immunogenic cell death cascade. Treated tumor cells release danger-associated molecular patternsVheat shock proteins and high-mobility group proteinsVwhich recruit and stimulate dendritic cell function within the tumor microenvironment. 29 Ionizing radiation also results in inflammatory responses and increased expression of cellular adhesion molecules and selectins, which leads to increased vascular permeability and delivery of immune cells. Radiation therapy has also been shown to enhance MHC class I expression on several tumor lines, leading to T-cell anti-tumor activity. 30 Based on these observations, vaccines and other immune modulators have been combined with radiation in numerous preclinical tumor models. 31 In vaccine studies, the addition of radiation augments the generation of antigen-specific cytotoxic T lymphocytes. 32 Because radiation also activates Toll-like receptors (TLRs), it has been combined with TLR agonists. 33, 34 When both radiation and the TLR agonist are delivered locally to a focal tumor site, a significant response has been observed at distant sites as well, presumably due to TLR effects on innate immune activity. 33, 34 Various immune-related cytokines (including tumor necrosis factor > [TNF->], IL-1, and IL6) have also been combined with radiation in mouse models. 35 As noted with other immune modulators, anti-tumor responses have been augmented at all sites of disease, irradiated or not. Efforts to combine these systemic immunoregulators with radiation therapy for lung cancer in the clinical setting have been limited, with concern regarding the potential for excessive normal tissue toxicity to lung parenchyma. It has also been shown that early dendritic cell migration to tumors may enhance radiation effects locally and distantly. 27, 36 Early-phase clinical trials have combined radiation with intratumoral dendritic cell injection. In a sarcoma study, this approach resulted in 70% 1-year disease-free survival, and 52% of patients mounted tumor-specific immune responses. 37 In a trial of single-fraction high-dose radiation plus intratumoral dendritic cell injection, there was limited toxicity, and nearly 50% of patients achieved a clinically significant response. 38 
TABLE 2. Effects of Radiation Therapy and Chemotherapy on Anti-tumor Immunity
Component of Immune Response Potential Effects of RT Potential Effects of Chemotherapy
Antigen presentation Translocation of calreticulin to cell surface activates dendritic cells and other APCs 7, 106 Increased antigen cross-presentation and dendritic cell activation 107 Enhanced MHC class I expression 30 Induction of immunogenic cell death 44 Release of danger-associated molecular patterns recruits and stimulates dendritic cells 29 
T-cell response, trafficking
Results in systemic inflammatory repsonse 39 Release of alarmin and binding to TLR4 activates anti-tumor immunity 108 Release of alarmin and binding to TLR4 activates anti-tumor immunity 108 Increased intratumoral T cell accumulation 111,112 CXCL16 release attracts effector T cells 109 Tumor vascular endothelial changes promote immune cell extravasation 8, 110 The abscopal effect. Generally, the effect of radiation on tumor cell death is most apparent at the irradiated sites. In the abscopal effect, distant, nonirradiated sites of disease also demonstrate reduction in tumor volume. Proposed mechanisms include radiation-associated dendritic cell recruitment, T-cell activation, increased vascular permeability, and increased antigen presentation. Abscopal effects appear to be more common when radiation is combined with immunotherapies.
The observation that distant, nonirradiated tumor sites may respond after focal radiotherapy is known as the abscopal effect ( Fig. 3) . Systemic inflammatory and immune responses to radiation appear to underlie this phenomenon. 29, 39 A recent phase I clinical trial evaluated patients with widespread melanoma and renal cell carcinoma treated with high-dose radiation to limited sites of gross disease followed by systemic IL-2 therapy. In most cases, significant responses were noted at nonirradiated as well as irradiated sites. More than half of patients had a complete metabolic response at all sites of disease. Among those patients demonstrating the greatest benefit, there were higher levels of circulating MHC class II T cells. 40 Similarly, a recently published case report described a patient with progressive metastatic melanoma (featuring hilar, liver, and paraspinous disease) while receiving the antiYCLTA-4 antibody ipilimumab. 41 For symptom control, the patient underwent short-course palliative radiation to the paraspinous mass, which was radiographically unchanged more than 1 month later. However, after reinitiation of ipilimumab, all sites of disease regressed considerably. Although the patient had received ipilimumab both before and after radiation, the timing of events suggests that the apparent abscopal effect was driven by postradiation ipilimumab doses.
Chemotherapy
Aside from cytotoxic properties, certain chemotherapeutic agents also alter anti-tumor immune responses. The degree to which this phenomenon occurs may depend on the type of cell death effected by a given chemotherapy drug. Apoptosis, an intrinsic mechanism of cell death, has traditionally been considered nonimmunogenic or possibly immune suppressive. Apoptotic cells express phosphatidylserine on the outer membrane leaflet as the plasma membrane loses its integrity. Phosphatidylserine functions as an immune down-regulator; it suppresses release of the proinflammatory cytokine IL-12 and stimulates production of the anti-inflammatory cytokines transforming growth factor A (TGF-A), IL-10, and prostaglandins. Anticancer drugs trigger apoptosis by death receptor (eg, FAS, TNF)Ydependent and Yindependent pathways. 42, 43 By contrast, nonapoptotic mechanisms, which include necrosis, autophagy, and mitotic catastrophe, are considered immunogenic. The alkylating agent temozolomide appears to induce G2/M arrest and autophagy but not apoptosis. 44 More recently, apoptosis has been acknowledged as potentially immunogenic, as the FAS and TNF pathways may promote CD8+ T cell direct lysis of tumor cell targets. In the setting of massive apoptosis, secondary necrosis may cause release of proinflammatory mediators including heat shock proteins, which in turn may stimulate dendritic cells. 45Y49 Through the initiation of cytotoxic tumor cell death, systemic chemotherapy may result in a plethora of immune effects: (1) deliver a larger range of diverse tumor antigens; (2) increase antigen cross presentation, stimulate dendritic cells, and prime APCs; (3) suppress immune tolerance for tumor; (4) increase T-cell access to tumor; (5) increase local tumor-antigen T-cell activation; (6) promote memory-based humoral effects against tumor; (7) suppress excessive immune negative regulatory events. 45Y49
DEVELOPMENT OF AND CLINICAL EXPERIENCE WITH VACCINES AND IMMUNOTHERAPIES IN LUNG CANCER
The characteristics of selected vaccines and other immunotherapies are listed in Tables 3 and 4 . Selected clinical trials using these agents for lung cancer are listed in Table 5 . Many but not all of these agents have been studied in locally advanced disease. Certain agents found not to be effective in other disease contexts, such as metastatic disease, have been included. Although drug development traditionally brings forward to earlier stages only those agents with efficacy in the metastatic setting, this paradigm may not hold true for vaccines and other immunotherapies, given the favorable conditions of locally advanced lung cancer for these treatment strategies. In general, this section focuses on phases II and III clinical trials, rather than case series.
Vaccines
For cancer treatment, vaccines are composed of 1 or more tumor antigens and an adjuvant. The antigen may be recombinant proteins, specific peptides, whole-tumor lysates, or irradiated tumor cells. 50 The adjuvant stimulates the immune response to the vaccine without having any specific intrinsic antigenic effect. Molecules used for this purpose include aluminum salts, oil suspensions, virosomes, TLR ligands, and immune cells such as dendritic cells. In addition, vaccination can be coordinated with microenvironments that render a tumor more immunogenic. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that evokes a powerful immune response. Bystander cell lines producing GM-CSF have been added to autologous patient tumor cell-based vaccines. 51Y53 Several vaccine strategies incorporate pretreatment with low-dose cyclophosphamide, which reduces the number and activity of immune-tolerant T-regulatory cells. Vaccines are generally well tolerated as lung cancer therapy, with local injection site reactions and flu-like symptoms the principal toxicities. 54Y56 Key to the development of tumor vaccines is the identification of tumor-specific antigen targets. The principal established antigen targets in NSCLC are melanoma-associated antigen A3 (MAGE-A3) and mucin 1 (or mucinous glycoprotein 1 [MUC-1]). Although not tumor-specific, the epidermal growth factor (EGF) ligand has also been targeted, based on the critical role of EGF ligand and receptor signaling in NSCLC. Although not covered in detail in this review, antigens identified as potential vaccine targets in small cell lung cancer include p53 and glycosphingolipid GD3. 57Y59 To limit the possibility that vaccine efficacy will diminish over time because of downregulation of expression of a single antigen, an alternate approach is to vaccinate against entire tumor cells (as can be achieved using tumor cell lines). 60, 61 Dendritic cell vaccine protocols are also being investigated. 62, 63 With this approach (exemplified by the approved sipuleucel-T vaccine for prostate cancer), host dendritic cells are exposed to antigen in vitro and then reinjected into patients. 62, 63 From dendritic and nondendritic vaccine efforts, toxicities have not been considered excessive to date.
Melanoma-Associated Antigen A3
Melanoma-associated antigen (MAGE) is a tumor-specific shared antigen with normal expression limited to placental trophoblasts and testicular germ cells. However, in those tissues, there is no antigen presentation due to lack of class I presenting molecules expressing the gene, making MAGE a highly tumor-specific target. MAGE is expressed in a variety of tumors, including melanoma, NSCLC, bladder, head and neck, esophageal, and liver. Its physiologic role is unknown. 64 Melanomaassociated antigen is expressed in approximately 35% of NSCLCs. MAGE expression is associated with histology (approximately 50% in squamous cases vs 25% in nonsquamous cases), stage (ranging from 16% in stage I to 35% in stage III to 50% in stage IV disease), and worse tumor-specific survival. 65Y68 The MAGE-A3 vaccine consists of purified MAGE-A3 recombinant protein in combination with a liposomal formulation containing the AS15 adjuvant system, which consists of protein D (a lipoprotein on the surface of Haemophilus influenzae B) and a polyhistidine tail. The importance of the vaccine adjuvant is evident in a phase II trial of 17 patients with resected early-stage NSCLC. Of 9 patients vaccinated with MAGE-A3 protein, 3 (33%) had an increase in antiYMAGE-A3 antibody titers as determined by enzyme-linked immunosorbent assay. In contrast, of 8 patients vaccinated with MAGE-A3 protein plus AS15 adjuvant, 7 (88%) had a substantial increase in antiYMAGE-A3 antibody titers. 69 The MAGE-A3 vaccine was evaluated in a double-blind phase II trial in completely resected stage IB/II NSCLC expressing MAGE-A3 (assessed by quantitative polymerase chain reaction). Vaccine was administered every 3 weeks for 5 doses (induction) then every 3 months for 8 doses (maintenance). No other adjuvant therapy was permitted. There was a trend toward benefit in disease-free interval (primary endpoint), disease-free survival, and overall survival. 70 A gene signature consisting of chemokines and T-cell markers was predictive of clinical benefit; in the overall population, there was a 25% reduction in risk of cancer recurrence versus 43% in patients with a positive gene signature. The gene profile had substantial overlap with one found to correlate with outcomes in an earlier melanoma clinical trial. 71 Although the phase II study did not include patients with locally advanced disease, the phase III MAGRIT (MAGE-A3 as Adjuvant, NSCLC Immunotherapy) trial (NCT00480025) includes resected stage IB-IIIA, A3-positive NSCLC. The trial, the largest adjuvant study ever conducted in lung cancer, screened 13,915 patients, randomized 2315 patients to vaccine or placebo, and completed enrollment in 2012.
Mucinous Glycoprotein 1
Mucinous glycoprotein 1 (mucin 1 or MUC-1) is a membraneassociated glycoprotein expressed on secretory epithelial cells. In cancer, it is overexpressed and aberrantly glycosylated. This version is antigenically distinct from that in normal tissue and functions as an oncogene, rendering it a suitable target for immunotherapy. 72 MUC1 1 expression is associated with cell transformation, immunosuppression, and resistance to chemotherapy. 73Y75
Liposomal BLP25
Liposomal BLP25 (L-BLP25) is a peptide vaccine targeting the exposed core peptide of MUC-1. It incorporates a synthetic MUC-1 lipopeptide and the immunoadjuvant monophosphoryl lipid A in a liposomal delivery system. Liposomal BLP25 is generally administered with low-dose cyclophosphamide to reduce T-regulatory cell activity and thereby enhance the elicited immune response. In lung cancer, the clinical development of L-BLP25 has been centered on locally advanced disease. 76Y78 In a randomized phase IIB study, 171 patients with stage IIIB or IV NSCLC with disease control after first-line chemotherapy or chemoradiation were assigned to L-BLP25or best supportive care. A single dose of cyclophosphamide (300 mg/m 2 up to 600 mg/m 2 ) was administered 3 days before the first dose of vaccine, which was given as 8 weekly vaccinations (1000 Hg) then maintenance vaccinations every 6 weeks starting week 13. In the overall population, survival favored the vaccine arm, with the greatest benefit noted in the subset of patients with stage IIIB disease (approximately 40% of the study population). In this group, median overall survival was 30.6 versus 13.3 months (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.30Y0.99). 76 Based on these promising results, 2 phase III trials in patients with unresectable stage III NSCLC with responding or stable disease after primary chemoradiation have been conducted. The START (Stimulating Targeted Antigenic Responses to NSCLC) trial (NCT01015443) was placed on clinical hold in 2010 when a patient with melanoma on an exploratory trial of L-LBP25 developed fatal encephalitis, which was ultimately deemed unrelated to study drug. Patients on the START study went an average of 5 months without therapy; those within 6 months of randomization (the period of more intensive therapy) were replaced, yielding a total enrollment of 1476 patients. In a December 2012 press release, it was reported that the START trial did not meet the primary endpoint of a statistically significant improvement in overall survival, but ''notable treatment effects were seen for L-BLP25 in certain subgroups.'' Further data are anticipated in 2013. The INSPIRE (Stimuvax trial in Asian NSCLC Patients: Stimulating Immune Response) (NCT00409188) has enrolled more than 400 patients in 5 Asian countries. Results have not yet been reported.
TG4010
The TG4010 vaccine comprises a suspension of recombinant vaccinia vector (modified vaccinia virus Ankara [MVA]) containing the coding sequence for human MUC-1 antigen and human IL-2 (Mva-Muc1-Il2). It has been studied in conjunction with chemotherapy in advanced MUC-1Ypositive NSCLC, where the combination was noted to be feasible and well tolerated and did not prevent induction of a cellular response against MUC-1. 79 In a randomized IIB trial, the primary endpoint of 6-month PFS rate was 43% with TG4010 versus 35% for chemotherapy alone. 56 The subset of patients with normal levels of activated natural killer cells at baseline (73% of the evaluable population) derived the greatest benefit, with median survival 17.1 months in the experimental arm versus 11.3 months in the control arm. A phase III trial is underway.
Belagenpumatucel-L
Belagenpumatucel-L is an allogeneic tumor cell vaccine cocktail that incorporates 4 irradiated NSCLC cell lines modified with TGF-A antisense plasmid. The rationale for this therapeutic approach is that NSCLC tumor cell lines appear to share immunogenic epitopes with primary tumors, as evidenced by cross-reactivity between cytotoxic T lymphocytes generated against human lung adenocarcinoma cell lines and other lung cancer cell lines. By using 4 cell lines (H460, H520, SKLU-1, RH2), the total number of tumor antigens in the vaccine is increased. The TGF-A antisense plasmid augments the immune response because TGF-A has a role in allowing tumors to escape host immunosurveillance by inhibiting cytotoxic T-cell activation and converting naive T cells to T-regulatory cells. 80 In NSCLC, there exists an inverse correlation between TGF-A concentration and survival. 81 In a dose-variable phase II trial, 75 patients with stage II-IV NSCLC with a total estimated tumor burden volume 125 mL or less were randomized to 1 of 3 doses of belagenpumatucel-L administered monthly or on alternate months for up to 16 doses. 82 In the highest dose cohort (5.0 Â 10 7 cell per injection intradermally), the 2-year survival rate in advanced disease was 47%. Responding patients were noted to have increased cytokine production (IFN-F and IL-6) and increased antibodymediated response to vaccine HLAs. In a separate phase II trial in advanced disease, median survival was approximately 19 months. 83 The phase III STOP (Survival, Tumor-free, Overall, and Progression-free) trial (NCT00676507) is ongoing. Patients in this trial have locally advanced or advanced NSCLC without progression after first-line chemotherapy or chemoradiation.
Other Vaccines in Development for Lung Cancer Therapy
The antigen PRAME (preferentially expressed antigen of melanoma) is expressed at low levels in only a limited set of normal adult cell types, among them testis, ovary, endometrium, kidney, and adrenal medulla. 84 It is also expressed in a variety of tumors, including melanoma and NSCLC. 85, 86 The precise function of PRAME is not well defined, but it appears to be associated with repression of retinoic acid receptor signaling and is thus implicated in regulation of cell cycle and cell death. 87 As the case for other tumor antigens, including MAGE-A3, its expression appears to be regulated by promoter region methylation. A dose escalation study of GSK2302032, which comprises a purified PRAME recombinant protein combined in a liposomal formulation containing the AS15 Adjuvant System, recruited patients with resected stage IB-IIIA NSCLC.
A vaccine targeting EGF ligand incorporating low-dose cyclophosphamide as an immunoadjuvant agent (CimaVax) has been studied in advanced NSCLC after 4 to 6 cycles of firstline platinum-based chemotherapy. Although the improvement in overall survival did not reach statistical significance in the overall population, it did so among patients who were younger than 60 years, had a robust immunologic response, or had a strong decrease in circulating EGF levels. 88, 89 The vaccine has received approval for clinical use in Cuba.
Vaccines consisting of autologous tumor cells engineered to express GM-CSF (which functions as an adjuvant to enhance production and migration of granulocytes) have been studied in advanced NSCLC. Production of these individualized therapies required surgical resection of a metastatic site, processing the resected tissue to single-cell suspension, infecting with replication-defective adenoviral vector encoding GM-CSF, irradiation, and cryopreservation. Lesions resected after vaccination revealed T-cell and plasma cell infiltrates and tumor necrosis in some patients, with prolonged disease control in a subset of cases. 90, 91 Immunotherapies
Checkpoint Inhibitors
In recent years, checkpoint inhibitors have emerged as the principal immunotherapies in development for cancer therapy (Fig. 2) . These monoclonal antibodies interfere with inhibitory pathways in the immune response, thereby augmenting antitumor immunity. The principal concern of this approach is the nonspecific nature of the response, which may result in considerable autoimmune effects. Furthermore, with immune-based therapy approaches, there can be a clear clinical benefit despite an initial apparent radiographic disease progression. As a result of this flare phenomenon, the concept of ''immune-related'' response criteria has been promoted in parallel to standard imaging criteria for traditional cytotoxic agents. Thus, the addition of immunotherapies to existing treatments of locally advanced NSCLC may further increase the high rates of treatment-related radiographic abnormalities that occur following conventional multimodality therapy. Clinically, the key pathways targeted, CTLA-4 and PD1, differ by toxicity and efficacy profiles.
Cytotoxic T-LymphocyteYAssociated Antigen 4
In addition to binding of the T-cell receptor on the surface of T cells to cancer cell antigens presented by the MHC on dendritic cells, T-cell activation requires signaling between costimulatory molecules. In the priming phase, which occurs in regional lymph nodes, dendritic cell costimulatory molecules B7-1 (or CD80) and B7-2 (or CD86) bind to CD28 (cluster of differentiation 28) on T cells to generate activation signals. When dendritic cells bind to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) on T cells, the interaction results in inhibitory signals. Via competitive binding, antiYCTLA-4 antibodies block this inhibitory pathway.
Ipilimumab (Yervoy) and tremelimumab are both fully human antiYCTLA-4 antibodies. As monotherapy, they have activity against melanoma, and ipilimumab has been approved for this indication. Principal toxicities include autoimmune dermatitis, colitis, hepatitis, thyroiditis, and hypophysitis (ie, hypopituitarism), requiring clinicians to recognize and treat these adverse events rapidly. In lung cancer, both agents have been combined with chemotherapy for the treatment of advanced disease. Ipilimumab was investigated in a 3-arm trial combined in a concurrent (starting cycle 1) or phased (starting cycle 3) approach with carboplatin-paclitaxel. The greatest benefit was seen in squamous tumors and with the phased approach, suggesting that pretreatment with chemotherapy augmented antitumor immune effects, either through tumor debulking or other mechanisms. 92 A phase III trial using this strategy is underway.
A phase II open-label trial of maintenance tremelimumab after first-line chemotherapy for advanced NSCLC resulted in a numerical improvement in progression-free survival, but this did not reach statistical significance. 93 
Programmed Death 1
In contrast to CTLA-4, the negative regulatory effects of the programmed death-1 (PD-1) pathway occur in the priming phase of the immune response in peripheral tissues. The PD-1 inhibitory receptor, which is expressed by T cells during prolonged antigen exposure, binds to PD ligand 1 (PD-L1) and PD-L2 expressed in the tumor microenvironment and within inflamed tissues, resulting in blockade of negative regulatory signals. AntiYPD-1 and antiYPD-L1 antibodies have slightly different mechanistic effects. Programmed death 1 blockade interferes with binding to PD-L1 and PD-L2 but does not have effects on B7. Programmed death ligand L1 blockade interferes with binding to PD-1 and B7 but does not impact PD-L2 binding, a distinction that may impact toxicity profiles.
Early clinical trials of PD-1Y and PD-L1Ydirected therapies suggest single-agent activity in lung cancer. In a dose-escalation trial of the antiYPD-1 antibody BMS-936558, nearly 20% of patients with NSCLC achieved radiographic response. These responses were durable in many cases. Clinical benefit appeared to be limited to patients with PD-L1Ypositive tumors. Immunerelated adverse effects appeared less common and less severe than those seen with antiYCLTA-4 antibodies. Nevertheless, grade 3 to 4 toxicity occurred in approximately 10% of patients, including 3 cases of fatal pneumonitis. 94 In a trial of the antiYPD-L1 antibody BMS-936559, radiographic response was achieved in approximately 10% of NSCLC cases, with similar rates of grade 3 to 4 toxicities. 95 In a number of cases, prolonged responses lasting months were noted. As these drugs arguably demonstrate the strongest anticancer activity in NSCLC of any immunotherapy to date, they are currently being compared with single-agent chemotherapy in phase II trials and studied in combination with multiple chemotherapy regimens and molecularly targeted agents in the phase I setting. These drugs have not been evaluated in locally advanced disease, where potential overlapping pulmonary toxicity with thoracic radiation therapy would be a theoretical concern.
TLR Ligands Toll-like receptor (TLR) ligands are membrane glycoproteins involved in the recognition of broad classes of microorganismassociated molecular structures. They have a role in both innate and adaptive immune responses. 96 Ligand binding to TLRs results in induction of proinflammatory cytokines and other antimicrobial compounds. Functionally active TLR9 is overexpressed in lung cancer compared with normal lung tissue. 97 PF-3512676 (formerly termed CpG 7909) is a synthetic TLR9activating oligodeoxynucleotide that mimics the natural ligand of TLR9 (unmethylated CpG motifs) that induces immune responses, potentially promoting anti-tumor effects. 98 In a randomized phase II study, the addition of PF-3512676 to first-line taxane-based chemotherapy resulted in a significant increase in response rate and a trend toward improved survival. 99 However, 2 phase III trials were closed at interim analysis due to crossing the predefined futility threshold for overall survival. 100, 101 The addition of PF-3512676 to chemotherapy resulted in increased hematologic adverse events, transfusions, infections, myeloid growth factor use, and chemotherapy dose delays and reductions.
Talactoferrin
Talactoferrin is a recombinant human lactoferrin purified from Aspergillus niger. Lactoferrin is an iron-binding glycoprotein with immunomodulatory properties. When administered orally, talactoferrin binds gut epithelium and is subsequently transported to gut-associated lymphoid tissue, where it recruits and induces maturation of circulating dendritic cells. In turn, these dendritic cells may have anti-tumor activity. Talactoferrin is not systemically absorbed; there are no increase in serum lactoferrin concentrations and no resulting talactoferrin-specific antibodies. In phase II trials, talactoferrin improved survival as monotherapy compared with placebo and in combination with chemotherapy. 102, 103 Talactoferrin was very well tolerated, with fewer adverse events than seen in the placebo arms. However, the international phase III FORTIS-M trial, which enrolled 720 patients with previously treated advanced NSCLC to talactoferrin or placebo, did not demonstrate a benefit for the primary endpoint of overall survival (median, 7.5 months with talactoferrin vs 7.7 months with placebo; HR, 1.04; P = 0.66) or for progression-free survival. 104 Following these negative results, the phase III FORTIS-C trial of carboplatin-paclitaxel T talactoferrin was stopped, with 94 of the planned 1100 patients enrolled. No difference in overall survival or progression-free survival was noted. 105 
CONCLUSIONS
Historically, vaccines and immunotherapies have had a limited role in the treatment of lung cancer. Lack of antigenic activity, immunosuppressive effects of the tumor, and difficulties debulking the disease in advanced stages all hinder the effects of these strategies. Recent years have seen several promising agents fail to improve clinical outcomes in phase III trials, including the L-BLP25 vaccine, TLR-targeting drugs, and talactoferrin. However, newly emerging approaches, such as immune checkpoint inhibition, demonstrate considerable promise in this challenging disease. Nowhere are these therapies of greater potential interest than in locally advanced NSCLC, a setting where disease debulking is feasible and radiotherapy and chemotherapy may enhance the effects of immunotherapies. Critical to moving forward with such an approach will be mitigation of potentially overlapping toxicities, optimizing dosing and schedule when combining immunotherapy with other treatment modalities, standardizing the approach to interpreting radiographic abnormalities during and after treatment, and the development of biomarkers to predict which patients are most likely to derive benefit.
